• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Raltegravir is safely used with long-term viral suppression for HIV-infected patients on hemodialysis: a pharmacokinetic study.

作者信息

Yanagisawa Kunio, Nagano Daisuke, Ogawa Yoshiyuki, Uchiumi Hideki, Shigehara Tetsuya, Saruki Kazuhisa, Handa Hiroshi, Araki Takuya, Yamamoto Koujirou, Nojima Yoshihisa

机构信息

aDepartment of Medicine and Clinical Science bDepartment of Clinical Pharmacology, Gunma University Graduate School of Medicine cJomo Ohashi Clinic dSaruki Clinic, Maebashi, Gunma, Japan.

出版信息

AIDS. 2016 Mar 27;30(6):970-2. doi: 10.1097/QAD.0000000000001012.

DOI:10.1097/QAD.0000000000001012
PMID:26959356
Abstract
摘要

相似文献

1
Raltegravir is safely used with long-term viral suppression for HIV-infected patients on hemodialysis: a pharmacokinetic study.
AIDS. 2016 Mar 27;30(6):970-2. doi: 10.1097/QAD.0000000000001012.
2
'How much raltegravir do you take?' The answer may not be so obvious: an accidental finding from clinical practice.
HIV Med. 2020 Feb;21(2):e1-e2. doi: 10.1111/hiv.12783. Epub 2019 Jul 23.
3
Reduced raltegravir clearance in HIV-infected liver transplant recipients: an unexpected interaction with immunosuppressive therapy?HIV感染的肝移植受者中拉替拉韦清除率降低：与免疫抑制治疗的意外相互作用？
J Antimicrob Chemother. 2016 May;71(5):1341-5. doi: 10.1093/jac/dkv466. Epub 2016 Jan 10.
4
Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.拉替拉韦在感染 HIV-1 的孕妇中的药代动力学、安全性和疗效。
Clin Infect Dis. 2015 Sep 1;61(5):809-16. doi: 10.1093/cid/civ366. Epub 2015 May 5.
5
Raltegravir/nevirapine dual therapy at reduced doses as 'maintenance' treatment in virally suppressed HIV-infected patients.
AIDS. 2015 Aug 24;29(13):1722-3. doi: 10.1097/QAD.0000000000000775.
6
Dose optimization of raltegravir chewable tablets in a 4-year-old HIV-infected child.4岁HIV感染儿童中拉替拉韦咀嚼片的剂量优化
Clin Infect Dis. 2015 Jul 15;61(2):294-5. doi: 10.1093/cid/civ290. Epub 2015 Apr 13.
7
Post-prandial lipid effects of raltegravir versus darunavir/ritonavir in HIV-1-infected adults commencing combination ART.拉替拉韦与达芦那韦/利托那韦对开始接受联合抗逆转录病毒治疗的HIV-1感染成人餐后血脂的影响。
J Antimicrob Chemother. 2016 Apr;71(4):1127-9. doi: 10.1093/jac/dkv436. Epub 2015 Dec 18.
8
Adverse events of raltegravir and dolutegravir.拉替拉韦和度鲁特韦的不良事件。
AIDS. 2017 Aug 24;31(13):1853-1858. doi: 10.1097/QAD.0000000000001590.
9
Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug-drug interactions (DDIs) with improved adherence and tolerability.
Sex Transm Infect. 2016 Mar;92(2):107. doi: 10.1136/sextrans-2015-052262.
10
A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIV.评估 HIV 感染者中每日一次服用利匹韦林 1200mg 时的暴露情况的群体药代动力学分析。
CPT Pharmacometrics Syst Pharmacol. 2021 Feb;10(2):161-172. doi: 10.1002/psp4.12586. Epub 2021 Jan 25.

引用本文的文献

1
Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.肾功能损害患者的新型抗逆转录病毒药物：临床和药代动力学考量
Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):559-572. doi: 10.1007/s13318-016-0394-6.